July 2015

New Product - Harvoni

Harvoni (ledipasvir/sofosbuvir) contains a HCV NS5A inhibitor (ledipasvir) and a nucleotide inhibitor of HCV NS5B RNA-dependent RNA polymerase (sofosbuvir). Harvoni is indicated for the treatment of chronic hepatitis C (CHC) genotype 1 infection in adults. Harvoni should not be administered concurrently with other medicinal products containing any of the same active components. Harvoni is available as a fixed dose combination tablet containing 90 mg of ledipasvir and 400 mg of sofosbuvir. Harvoni is available as a bottle of 28 tablets.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au